Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 11Terminated 6Withdrawn 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Supratentorial Neoplasms 1Gliosarcoma 1Glioblastoma 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × lonafarnib × Clear all
NCT00102648 2024-10-17

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
34 enrolled
CNSSarcoma

Glioblastoma, Supratentorial Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡